Excella-Bio: Excellence in Innovation
Excella-Bio is first and foremost a CRO that creates cash flow from doing Phase I-II studies for all biopharmaceutical companies looking to reduce operational inefficiencies in their clinical trial operations as well as obtain a significant reduction in clinical research expenses. Our business model allows Excella-Bio to do studies in less time for less money. Our CRO is unique in not only the fact that we do the studies, but we collect specialized data from each patient in the study which gives us a unique insight into the disease and is beneficial both clinically and financially. This data includes biomarkers and statistical trends that we can then use in the treatment of future patients.
In addition to our CRO, Excella-Bio is looking for an investment to build a Point of Care Cell Therapy Center. Cell therapy is perhaps the most important innovation of this generation. This center would expand our CRO capacity and make us a more valuable partner to our biopharmaceutical sponsors.
Excella-Bio will use this Cell Therapy Center for:
CART-T therapy –developing our own drugs
Do studies for Big Pharma and Biotech companies.
After the initial investment of building the Cell Therapy Center, we can duplicate it at other locations. Because of the multifaceted use of The Center, we believe we can be profitable at these centers in two years.
Science and Industry can come together in a community supported network to develop a new cell therapy treatment modality in a time and cost effective method. This cell therapy center will examine and study the alternative to current toxic therapies.
Our management team has extensive and unique experience in regulated cell therapy development, including contract research, development and manufacturing across a broad range of science, technologies and process operations. Members of our scientific advisory team are leaders in in the fields of immunology, virology, cell biology clinical immunotherapy, regulatory and data management. To learn more about our Key Executive team please click here.
Our expertise is focused on advancing product candidates from conception through the clinic by reducing manufacturing risks, shortening the time to regulatory approval and lowering the overall costs of a clinical development program that meet applicable quality standards.